CARY, N.C., Sept. 2 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), is launching a series of scientific seminars, "An Accelerated Path to Proof-of-Concept in Drug Development," designed to help pharmaceutical and biotechnology researchers learn the latest innovations in Phase I and IIa clinical trial designs. The sessions will familiarize attendees with techniques and study designs to save time and money when bringing new drugs to market. The seven-city series starts on September 15 in Princeton, N.J., and ends on October 21 in San Diego.
"We know that pharmaceutical and biotechnology companies are under increased pressure to get drugs to market as soon as possible. Identifying viable drug candidates quickly allows resources to be used more strategically," said Dr. Troy McCall, CEO of Cetero Research. "Through this seminar series, we can share our expertise and best practices in accelerating the drug development process. Some of the techniques we will be discussing have been shown to cut clinical trial timelines in half and reduce costs by more than 10 percent."
The seminars will focus on three topics: combined Phase I and IIa studies to accelerate proof-of-concept, biomarker fit-for-purpose assays and advanced population PK/PD modeling/analysis. Industry experts will share information and real-life case studies about the accelerated proof-of-concept (AcPOC) study designs and how to select the appropriate level of validation for biomarker assays to ensure that studies meet the current guidance. In addition, Cetero executives will discuss lessons learned from conducting more than 10,000 clinical pharmacology studies in a range of therapeutic areas, working with both healthy participants and patient populations.
"Our case studies demonstrate how the AcPOC study design can combine multiple trials – including single ascending dose (SAD), multiple ascending dose (MAD), preliminary interaction and proof-of-concept (POC) – into one study," said Dr. Graham Wood, President of Clinical Operations for Cetero's Toronto and Miami facilities and one of the speakers in the series. "In one allergy study for a major pharmaceutical company, we went from first patient, first visit, to top-line POC results in just 16 weeks, instead of the average 32 weeks. The savings in time and money, as well as the ability to get actionable data earlier, are major advantages for our sponsors in today's environment."
Each seminar will last approximately two hours and feature three presentations with question and answer sessions. The series schedule is as follows:
About Cetero Research
Cetero Research is the leading early-stage contract research organization (CRO). With more than 25 years of experience from its founding companies, Cetero has conducted more than 10,000 clinical pharmacology studies – more than any other CRO. Cetero's proven track record allows the company to provide flexible and high-quality drug-development services. The company's time-tested systems produce consistent and reliable data clients can trust. Cetero's clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. For more information, visit www.cetero.com, or call 877.7CETERO.
|SOURCE Cetero Research|
Copyright©2010 PR Newswire.
All rights reserved